|
1. Amarante-Medndes, G.P., Naekyung Kim, C., Liu, L., Huang,
Y., Perkins, C.L., Greens, D.R., Bhala, K., 1998, “Ber-Abl
exerts its antiapoptotic effect against diverse apoptotic
stimuli through blockage of mitochondrial release of
cytochrome C and activation of caspase-3,” Blood,
Vol. 91, pp. 1700-1705.
2. Anttonen, A., Kajanti, M., Heikkila, P., Jalkanen, M.,
Joensuu, H., 1999, “Syndecan-1 expression has prognostic
significance in head and neck carcinoma,” Br. J. Cancer,
Vol.79, pp.558-64.
3. Boise, L.H., Gonzalez-Garcia, H., Postema, C.E., Ding, L.,
Dindsten, T., Turka, C.A., Maox, N.G., Thompson, C.B., 1993,
“Bcl-x a dominant regulator of apoptotic cell death,” Cell,
Vol. 74, pp. 597-608.
4. Boucher, B.J., Mannan, N., 2002, “ Metabolic effects of the
consumption of Areca catechu,” [Review] [60 refs] Addict.
Biol., Vol. 7, pp. 103-110.
5. Charous, S.J., Stricklin, G.P., Nanney, L.B., Netterville,
J.L., Burkey, B.B., 1997, “ Expression of matrix
metalloproteinases and tissue inhibitor of
metalloproteinases in head and neck squamous cell carcinoma.
Ann. Otol. Rhinol. Laryngol., Vol.80, pp.1412-1419.
6. Chen, W.S., Wei, S.J., Liu, J.M., Hsiao, M., Lin, J.K.,
Yang, W.K., 2001, “ Tumor invasiveness and liver metastasis
of colon cancer cells correlated with cyclooxygenase-2 (COX-
2) expression and inhibited by a COX-2 selective inhibitor,
Etodolac,” Int. J. Cancer., Vol. 91,
pp. 894-899.
7. Cianchi, F., Cortesini, C., Bechi, P., Fantappie, O.,
Messerini, L., Vannacci, A., Sardi, I., Baroni, G., Boddi,
V., Mazzanti, R., Masini, E., 2001, “Up-regulation of
cyclooxygenase 2 gene expression correlates with tumor
angiogenesis in human colorectal cancer,” Gastroenterol.,
Vol. 121, pp. 1339-1347
8. Corcoran, M.L., Stetler-Stevenson, W.G., Dewitt, D.L., Watl,
L.M., 1994, “Effect of cholera toxin and pertussis toxin on
prostaglandin H synthase-2, prostahgandin E2, and matrix
metalloproteinase production by human monocytes,” Arch
Biochem. Biophys., Vol. 30, pp. 481-488.
9. Daimon, H., Sawada, S., Asakura, S., Sagami, F., 1998, “In
vivo genotoxicity and DNA adduct levels in the liver of rats
treated with safrole,” Carcinogenesis, Vol. 19, pp.141-146.
10. Das, C.M., Schantz, S.P., Shillitoe, E.J., 1993, “Antibody
to a mutagenic peptide of herpes simplex virus in young
adult patients with cancer of the head and neck” Oral Surg.
Oral Med. Oral Pathol. Oral Radiol. Endod., Vol. 75, pp. 610-
614.
11. Dubois, R.N., Abramson, S.B., Crofford, L., Gupta, R.A.,
Simon, L.S., Van De Putte, L.B., Lipsky, P.E., 1998, “
Cyclooxygenase in biology and disease,” [Review]
[117 refs] FASEB. J., Vol. 12, pp. 1063-73.
12. el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B.,
Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzier,
K.W., Vogelstein, B., 1993, “WAF1, a potential mediator of
p53 tumor suppression,” Cell, Vol. 75, pp. 817-822.
13. Gilhooly, E.M., Rose, D.P., 1999, “The association between
a muted ras gene and cyclooxygenase-2 expression in human
breast cancer cell line,” Int. J. Oncol., Vol. 15, pp. 267-
270.
14. Gleich, L.L., Salamone, F.N., 2002, “Molecular genetics of
head and neck cancer,” [Review] [107 refs] Cancer Control,
Vol. 9, pp. 369-378.
15. Grosch, S., Tegeder, I., Niederberger, E., Brautigam, L.,
Geisslinger, G., 2001, “COX-2 independent induction of
cell cycle arrest and apoptosis in colon cancer cells by
the selective COX-2 inhibitor celecoxib,” FASEB J., Vol.
15, pp. 27421-27424.
16. Gupta, S., Srivastava. M., Ahmad, N., Bostwick, D.G.,
Mukhtar, H.,2000, “Over-expression of cyclooxygenase-2 in
human prostate adenocarcinoma,” Prostate, Vol.42, pp. 73-
78.
17. Hamelin, R., Laurent-Pug, P., Oschwang, S., Jego, N.,
Asselain, B., Rvikos, Y., Girodet, J., Salmon, R.J.,
Thomas, G., 1994, “Association of p53 mutations with short
survival in colorectal cancer,” Gastroenterol., Vol. 106,
pp. 42-46.
18. Ho, C.M., Lam, K.H., Wei, W.I., Yuen, P.W., Lam, C.K.,
1993, “Squamous cell carcinoma of the hypopharynx -
analysis of treatment results,” Head Neck, Vol. 15, pp.
405-412.
19. Ho, P.S., Ko, Y.C., Yang, Y.H., Shieh, T.Y., Tsai, C.C.,
2002, “The incidence of oropharyngeal cancer in Taiwan:
an endemic betel quid chewing area,” J. Oral. Pathol.
Med., Vol. 31, pp. 213-219.
20. Hong, S.D., Hong, S.P., Lee, J.I., Lim, C.Y., 2000,
“Expression of matrix metalloproteinase-2 and -9 in oral
squamous cell carcinomas with regard to the metastatic
potential,” Oral Oncol.,Vol. 36, pp.207-213.
21. Hull, M., Lieb, K., Fiebich, BL., 2002, “Pathways of
inflammatory action in Alzheimer’s disease : potential
targets for disease modifying drugs,” Curr. Med. Chem.,
Vol.9, pp. 83-88.
22. Johnson, J.T., Bacon, G.W., Myers, E.N., Wagner, R.L.,
1994, “ Medial vs lateral wall pyriform sinus carcinoma:
implications for management of regional lymphatics, “ Head
Neck, Vol. 16, pp. 401-405.
23. Jeng, J.H., Chang, M.C., Hahn, L.J., 2001, “ Role of areca
nut in betel quid-associated chemical carcinogenesis:
current awareness and future perspectives,”[Review] [145
refs] Oral Oncol., Vol. 37, pp. 477-492.
24. Jones, M.K., Wang, H., Peskar, B.M., Levin, E., Itani,
.M., Sarfeh, I.J., Tarnawski, A.S., 1999, “Inhibition of
angiogenesis by nonsteroidal anti-inflammary drugs :
Insight into mechanisms and implications for cancer growth
and ulcer healing,” Nat. Med., Vol. 5, pp. 1418-1423.
25. Kerr, J.F., Wyllie, A.H., Currie, A.R., 1972, “ Apoptosis:
a basic biological phenomenon with wide-ranging
implications in tissue kinetics,” [Review] [68 refs]
Br. J. Cancer, Vol.26, pp. 239-257.
26. Keyomarsi, K., Tucker, S.L., Buchholz, T.A., Callister, M.,
Ding, Y., Hortobagyi, G.N., Bedrosian, I., Knickerbocker,
C., Toyofuku, W., Lowe, M., Herliczek. T.W., Bacus, S.S.,
2002, “Cyclin E and survival in patients with breast
cancer. N. Engl. J. Med., Vol. 347, pp. 1566-1575.
27. Ko, Y.C., Chiang, T.A., Chang, S.J., Hsieh, S.F., 1992,
“Prevalence of betel guit chewing habit in Taiwan and
related sociodemographic factors,” J. Oral. Pathol.
Med., Vol. 21, pp. 261-264.
28. Koga, H. Sakisaka, S. Ohishi, M., 1999 “Expression of
cyclooxygenase-2 in human hepatocellular carcinoma:
relevance to tumor dedifferentiation,” Hepatology, Vol.
29, pp. 688-696.
29. Ko, Y.C., Hung, Y.L., Lee, C.H., Chen, M.J., Lin, L.M.,
Tsai, C.C., 1995, “Betel quid chewing, cigarette smoking
and alochol consumption related to oral cancer in Taiwan,”
J. Oral. Pathol. Med., Vol.24, pp. 450-453.
30. Kok, S.H., Lee. J.J., Hsu, H.C., Chiang, C.P., Kuo, Y.S.,
Kuo, M.Y., 2002, “Mutations of the adenomatous polyposis
coli gene in areca quid and tobacco-associated oral
squamous cell carcinomas in Taiwan. J. Oral. Pathol. Med.,
Vol. 31, pp. 395-401.
31. Kondo, M., Yamamoto, H., Nagano, H., Okami, J., Ito, Y.,
Shimizu, J., Eguchi, H., Miyamoto, A., Dono, K., Umeshita,
K., Matsuura, N., Wakasa, K., Nakamori, S., Sakon, M.,
Monden, M., 1999, “Increased expression of COX-2 in
nontumor liver tissue Is associated with shorter disease-
free survival in patients with hepatocellular carcinoma,”
Clin. Cancer Res., Vol. 5, pp. 4005-4012.
32. Kudo, Y., Takata, T., Ogawa, I., Kaneda, T., Sato, S.,
Takekoshi, T., Zhao, M., Miyauchi, M., Nikai, H., 2000,
“p27Kip1 accumulation by inhibition of proteasome function
induces apoptosis in oral squamous cell carcinoma cells,”
Clin. Cancer Res., Vol. 6, pp. 916.
33. Kusukawa, J., Sasaguri, Y., Shima, I., Kameyama, T.,
Morimatsu, M.,1993, “Expression of matrix
metalloproteinase-2 related to lymph node metastasis of
oralsquamous cell carcinoma. A clinicopathologic study,”
Am. J. Clin. Pathol., Vol. 99, pp. 18-23.
34. Langenbach, R., Loftin, C.D., Lee, C., Tiano, H., 1999, “
Cyclooxygenase-deficient mice. A summary of their
characteristics and susceptibilities to inflammation and
carcinogensis,” Ann. N. Y. Acad. Sci., Vol. 889, pp. 52-61.
35. Lin, D.T., Subbaramaiah, K., shah, J.P., Dannenberg, Boyle,
J.O., 2002, “Cyc1ooxygenases-2 : a novel molecular target
or the prevention and treatment of head and neck cancer,”
[Review] [97 refs] Head Neck, Vol. 24, pp. 792-799.
36. Leahy, K.M., Ornberg, R.L., Wang, Y., Zweifel, B.S., Koki,
A.T., Masferrer, J.L., 2002, “ Cyclooxygenase-2 inhibition
by celecoxib reduced proliferation in induces apoptosis in
angiogenic endothelial cells in vivo,” Cancer Res., Vol.
62 pp. 625-631.
37. Lowe, S.W., Ruley, H.E., Jacks, T., Housman, D.E., 1993,
“P53-dependent apoptosis modulates the cytotoxicity of
anticancer agents,” Cell, Vol. 74, pp. 957-967.
38. Marks, S.C., Lolachi, C.M., Shamsa, F., Robinson, K., Aref,
A., Jacobs, J.R., 1996, “Outcome of pyriform sinus cancer:
a retrospective institutional review,” Laryngoscope., Vol.
106, pp. 27-31.
39. Masferrer, J.L., Leahy, K.M., Koki, A.T., Zweifel, B.S.,
Settle, S.L., Woerner, B.M., Edwards, D.A., Flickinger,
A.G., Moore, R.J., Seibert, K., 2000, “ Antiangiogenic and
antitumor activities of cyclooxygenase-2 inhibitors,”
Cancer Res., Vol. 60, pp. 1306-1311.
40. Mitchell, J.A., Warner, T.D., 1999, “Cyclooxygenase-2 :
pharmacology, physiology, biochemistry and relevance to
NSAID therapy,” Br. J. Pharmacol., Vol. 128, pp. 121-132.
41. Oh, S.J., Jeltsch, M.M., Birkenhager, R,, McCarthy, J.E.,
Weich, H.A., Christ, B., Alitalo, K., Wilting, J., 1997,
“VEGF and VEGF-C: specific induction of angiogenesis and
lymphangiogenesis in the differentiated avian
chorioallantoic membrane,” Deve. Biol., Vol.188, pp. 96-
109.
42. Ota, S., Bamba, H., Kato, A., Kawamoto, C., Yoshida, Y.,
Fujiwara, K., 2002, “COX-2, prostanoids and colon
cancer,” [Review] [44 refs] Aliment. Pharmacol. Ther.,
Vol. 16, pp.102-106.
43. Petrocelli, T., Poon, R., Drucker, D.J., Slingerland, J.M.,
Rosen, C.F., 1996, “UVB radiation induces p21 Cip1/waf1
and mediates G1 and S phase checkpoints,” Oncogene, Vol.
12, pp. 1387-1396.
44. Paccani, S.R., Boncristiano, M., Ulivieri, C., D’Elions,
M.M., Prete, G.D., Baldari, C., 2002, “ Nonsteroidal anti-
inflammatory drugs suppress T-cell activation by inhibiting
p38 MAPK induction,” J. Biol. Chem., Vol. 277 pp. 1509-
1513.
45. Randerath, K., Haglund, R.E., Phillips, D.H., 1984 “32p-
post-labelling analysis of DNA adducts formed in the livers
of animals treated with safrole, estragole and other
naturally-occurring alkenglbenzenes I adult female CD-1
mice,” Carcinogenesis, Vol. 5, pp. 1613-1622.
46. Ranelletti, F.O., Almadori, G., Rocca, B., 2001
“Prognostic significance of cyclooxygenase-2 in laryngeal
squamous cell carcinoma,” Int. J. Cancer, Vol. 95, pp.
343-349.
47. Rice, P.L., Goldberg, R.J., Ray, E.C., Driggers, L.J.,
Ahnen, D.J., 2001, “ Inhibtion of extracellular signal-
regulated kinase 1/2 phosphorylation and induction of
apoptosis by sulindac metabolites,” Cancer Res., Vol. 61,
pp. 1541-1547.
48. Riley, S.C., Webb, C.J., Leask, R., McCaig, F.M., Howe,
D.C., 2000, “Involvement of matrix metalloproteinases 2
and 9, tissue inhibitor of metalloproteinases and apoptosis
in tissue remodelling in the sheep placenta,” J. Reprod.
Fertil., Vol.118, pp. 19-27.
49. Serrano, M., Hannon, G.J., Beach, D., 1993, “a new
regwlatory motif in cell-cycle contro l causing specific
inhibition of cychn D/CDK4,” Nature Vol. 366, pp. 704-707.
50. Shiff, S.J., Rigas, B., 1997, “ Nonsteroid anti-
inflammatory drogs and colorectal cancer : envoling
concepts of their chemopreventive actions,”
Gastroenterol., Vol. 113, pp. 1992-1998.
51. Simon, C., Hicks, M.J., Nemechek, A.J., Mehta, R.,
O'Malley, B.W., Goepfert, H., Flaitz, C.M., Boyd, D., 1999,
“ PD 098059, an inhibitor of ERK1 activation, attenuates
the in vivo invasiveness of head and neck squamous cell
carcinoma,” Br. J. Cancer, Vol. 80, pp. 1412-1419.
52. Su, C.Y., Hwang, C.F., 1993, “ Near-total
laryngopharyngectomy with pectoralis major myocutaneous
flap in advanced pyriform carcinoma. J. Laryngol. Otol.,
Vol. 107, pp. 817-820.
53. Rozic, J.G., Chakrabory, C., Lala, P.K., 2001, “
Cyclooxygenase inhibitors retard murine mammary tumor
progression by reducing tumor cell migration, invasiveness
and angiogenesis,” Int. J. Cancer, Vol. 93, pp. 497-506.
54. Sawaoka, H., Tsuji, S.,, Tsujii, M., Gunawan, E.S., Sasaki,
Y., Kawano, S., Hori, M., 1999, “Cyclooxygenase inhibitors
suppress angiogenesis and reduce tumor growth in vivo,”
Lab. Invest., Vol. 79, pp. 1469-1477.
55. Sherr, C.J., 1993, “Mammalian G1 cyclins,” Cell, Vol. 73
pp. 1059-1065.
56. Shiff, S.J., Rigas, B., 1997, “ Nonsteroid anti-
inflammatory drogs and colorectal cancer : envoling concepts
of their chemopreventive actions,” Gastroenterol.,” Vol.
113, pp. 1992-1998.
57. Simon, L.S., 1999, “Role and regulation of cyclooxygenase-
2 during inflammation,” Am. J. Med., Vol. 106, pp. 37-42.
58. Takahashi, Y., Kawahara, F., Noguchi, M., Miwa, K., Sato,
., Seiki, M., Inoue, H., Tanabe, T., Yoshimoto, T., 1999,
“ Activation of matrix metalloproteinase-2 in human breast
cancer cells overexpressing cyclooxygenase-1 or —2,”
FEBS. Lett., Vol. 460, pp. 145-148.
59. Thun, M.J., Namboodiri, M.M., Heath, C.W., 1991, “Aspirin
use and reduced risk of fetal colon cancer,” N. Engl.
J.Med., Vol. 325, pp. 1593-1596.
60. Thyss, A., Schneider, M., Santini, J., Caldani, C.,
Vallicioni, J., Chauvel, P., Demard, F., 1986, “Induction
chemotherapy with cis-platinum and 5-fluorouracil for
squamous cell carcinoma of the head and neck,” Br. J.
Cancer, Vol. 54, pp. 755-60.
61. Tsujii, M., Kawano, S., DuBois, R.N., 1997,
“Cyclooxygenase-2 expression in human colon cancer cells
increases metastatic potential,” Proc. Natl. Acad. Sci.,
Vol. 94, pp. 3336-3340.
62. van den Heuvel, S., Harlow, E., 1993, “ Distinct roles for
cyclin-dependent kinases in cell cycle control,” Science,
Vol. 262,pp. 2051-2054.
63. Vainio, H., Morgan, G., 1998, “Cyclooxygenase-2 and breast
cancer prevention. Non- steriodal anti-inflammatory agents
are worth testing in breast cancer,” BMJ., Vol. 317, pp.
828.
64. Weitzman, S.A., Gordon, L.I., 1990, “Inflammation and
cancer: role of phagocyte-generated oxidants in
carcinogenesis,” Blood, Vol. 76, pp. 655-663.
65. Willoughby, D.A., Moore, A.R., Colville-Nash, P.R., 2000,
“COX-1, COX-2, and COX-3 and the future treatment of
chronic inflammatory disease,” Lancet, Vol. 355, pp. 646-
648.
66. Yang, C.Y., Meng, C.L., 1994, “Regulation of PG synthase
by EGF and PDGF in human oral, breast, stomach, and
fibrosarcoma cancer cell line,” J. Dent. Res., Vol. 73,
pp. 1407-1415.
67. Yatabe, Y., Masuda, A., Koshikawa, T., Nakamura, S.,
Kuroishi, T., Osada, H., Taahashi, T., Mitsudomi, T.,
Takahashi, T., 1998, “p27KIP1 in human lung cancers:
differential changes in small cell and non-small cell
carcinomas,” Cancer Res., Vol. 58, pp. 1042-1047.
68. Yoshizaki, T., Maruyama, Y., Sato, H., Furukawa, M., 2001
“Expression of tissue inhibitor of matrix metalloproteinase-
2 correlates with activation of matrix metalloproteinase-2
and predicts poor prognosis in tongue squamous cell
carcinoma,” Int. J. Cancer, Vol. 95 pp. 44-50
69. Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi,
K., Beach, D.,1993, “p21 is a universal inhibitor of
cyclin kinases,” Nature, Vol. 366, pp. 701-702.
70. Zhang, Y., Dewitt, D.L., McNeely, T.B., Wahl, S.M., Wahl,
L.M., 1997, “ Secretory leukocyte protease inhibitor
suppresses the production of monocyte prostaglandin H
synthase-2, prostaglandin E2, and matrix metalloproteinase.
J. Clin. Invest.,” Vol. 99, pp. 894-900.
|